Table 1 Demographic and clinical characteristics of study participants
Age | Sex | CD4 counta | Duration in Care (Years) | VL | Months between VLs | BMIb |
|---|---|---|---|---|---|---|
Elite controllers | ||||||
53 | F | 1245 | 10 | Undetectable | 8 | 33.9 |
38 | F | 919 | 9 | Undetectable | 12 | 18.9 |
36 | F | 1188 | 7 | Undetectable | 8 | 38.5 |
56 | M | 833 | 7 | Undetectable | 9 | 17.2 |
42 | F | 909 | 5 | Undetectable | 9 | 31.8 |
30 | F | 1050 | 5 | Undetectable | 10 | 29.3 |
37 | F | 728 | 6 | Undetectable | 9 | 23.9 |
40 | F | 994 | 10 | Undetectable | 9 | 32.3 |
41 | M | 778 | 9 | Undetectable | 12 | 25.2 |
37 | F | 1063 | 6 | Undetectable | 8 | 26.1 |
Non-controllers | ||||||
40 | M | 920 | 6 | 10,500 | 6 | 27.2 |
41 | F | 1192 | 6 | 2840 | 10 | 37.5 |
40 | F | 940 | 5 | 10,800 | 15 | 26.3 |
29 | F | 747 | 5 | 14,800 | 8 | – |
43 | F | 781 | 8 | 2310 | 8 | 32.7 |
38 | F | 589 | 5 | 75,100 | 10 | 21.4 |
42 | F | 1021 | 8 | 5250 | 6 | 21.3 |
41 | F | 852 | 10 | 2850 | 7 | 30.2 |